Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
KPTI Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 11, 2026
Report Source: 2026 1st Quarter Report
Karyopharm Therapeutics Inc. Stock Analysis KPTI
United States Health Care Micro Cap Report: Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. The company is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Read More Karyopharm Therapeutics Inc (KPTI) Chart
Key Statistics of Karyopharm Therapeutics Inc (KPTI)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$8.89Volume
711.99KP/E Ratio (TTM)
-52 Week Range
Market Cap
182.66MAvg. Volume
376.61KDividend Yield
-Financial Metrics & Statements of Karyopharm Therapeutics Inc (KPTI)
FAQ's for Karyopharm Therapeutics Inc (KPTI)
- According to Musaffa’s Shariah screening methodology, Karyopharm Therapeutics Inc (KPTI) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Karyopharm Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Karyopharm Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Karyopharm Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Karyopharm Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Karyopharm Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.